Shopping Cart
- Remove All
Your shopping cart is currently empty
BT-GSI, a γ-secretase inhibitor (GSI) with bone-targeting capabilities, effectively inhibits Notch signaling. Exhibiting dual action, it possesses both anti-myeloma and anti-resorptive properties, making it a promising candidate for research into multiple myeloma and related bone diseases. Additionally, BT-GSI demonstrates potential in inhibiting tumor growth and the progression of osteolytic disease.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,970 | 8-10 weeks | |
| 50 mg | $2,580 | 8-10 weeks | |
| 100 mg | $3,400 | 8-10 weeks |
| Description | BT-GSI, a γ-secretase inhibitor (GSI) with bone-targeting capabilities, effectively inhibits Notch signaling. Exhibiting dual action, it possesses both anti-myeloma and anti-resorptive properties, making it a promising candidate for research into multiple myeloma and related bone diseases. Additionally, BT-GSI demonstrates potential in inhibiting tumor growth and the progression of osteolytic disease. |
| Molecular Weight | 730.52 |
| Formula | C26H46BrN5O10P2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.